Company news

Share this article:

IMS Health announced the launch of its IMS Precision Compensation offering to help pharmaceutical companies optimize their sales force incentive compensation programs and gain additional cost efficiencies. To deliver this new solution, IMS has established an alliance with Callidus Software, a leading provider of sales performance management software. “Pharmaceutical companies are looking for new ways to drive commercial excellence and realize cost efficiencies, especially in non-core areas of their businesses,” said Sati Sian, general manager, Sales Force Effectiveness, IMS.

Teva Specialty Pharmaceuticals, the US respiratory therapy unit of Teva Pharmaceutical Industries and UCB announced an agreement to co-commercialize Teva's US respiratory medicines. The initial product to be jointly promoted in the US is Teva's ProAir HFA (albuterol sulfate) inhalation aerosol. ProAir HFA is the number-one branded hydrofluroalkane (HFA) albuterol sulfate inhaler in the US. Additionally, the agreement will provide UCB future joint promotion opportunities with other products in development by Teva Specialty Pharmaceuticals. Financial terms of the agreement were not disclosed.

Share this article:
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.